Principal Financial Group
FPRX

Principal Financial Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Principal Financial Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,877
Closed -$393K – 2311
2017
Q1 		$393K Sell
10,877
-4,722
-30% -$208K ﹤0.01% 1959
2016
Q4 		$782K Buy
15,599
+10,901
+232% +$573K ﹤0.01% 1853
2016
Q3 		$247K Buy
+4,698
New +$224K ﹤0.01% 1993

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Principal Financial Group's FPRX Position: Q2 2017 in Review

Principal Financial Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 10,877 shares — an estimated $393K sold.

Principal Financial Group first reported a position in FPRX in Q3 2016 and held it in 3 quarters. The position peaked at $782K in Q4 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Principal Financial Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Principal Financial Group sold 10,877 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $393K.
  • Principal Financial Group first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 3 quarters.
  • Principal Financial Group's Five Prime Therapeutics, Inc. position peaked at $782K in Q4 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Principal Financial Group's 13F filing for Q2 2017, filed 8 Aug 2017.